Conditions
Squamous Cell Carcinoma of Head and Neck
Trial Purpose
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with chemotherapy and immunotherapy, but the cancer gets worse.
The goal of this study is to learn if more people who receive lenvatinib and pembrolizumab have their cancer respond to treatment (the cancer gets smaller or goes away) than people who receive standard chemotherapy treatment.
NATIONAL TRIAL REFERENCE NUMBER
NCT04428151
EudraCT
2019-000569-19
EU CT
2022-500820-31
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Trial
All patients who enrol in the trial will receive medication while on the study.37.5% will receive pembrolizumab along with lenvatinib
37.5% will receive standard of care chemotherapy (docetaxel, paclitaxel, cetuximab or capecitabine)*
25% will receive lenvatinib alone
*Your doctor will decide which treatment is best for you
Trial Phase
Trial Phase 2
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Trial start and end dates
- Actual study start date 6 August 2020
- Estimated primary completion date 18 August 2024
- Estimated study completion date 18 August 2024
Trial locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about